152 related articles for article (PubMed ID: 17506483)
1. Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.
Tsao KC; Hong JH; Wu TL; Chang PY; Sun CF; Wu JT
J Clin Lab Anal; 2007; 21(3):193-6. PubMed ID: 17506483
[TBL] [Abstract][Full Text] [Related]
2. Oncological markers CA-125, CA 19-9 and endometriosis.
Fiala L; Bob P; Raboch J
Medicine (Baltimore); 2018 Dec; 97(51):e13759. PubMed ID: 30572523
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
4. [The determination of CA-125, CA-19-9 and CEA antigens in gynecologic patients for differential diagnosis and the assessment of the efficacy of surgical treatment and subsequent monitoring].
Alekseeva ML; Andreeva EN; Novikov EA; Fanchenko ND; Seliverstov AA; Bobkova MV; Margiani FR
Akush Ginekol (Mosk); 1995; (5):25-8. PubMed ID: 8579200
[TBL] [Abstract][Full Text] [Related]
5. Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.
Mikkelsen G; Åsberg A; Hultström ME; Aasarød K; Hov GG
Int J Biol Markers; 2017 Oct; 32(4):e461-e466. PubMed ID: 28561881
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
[TBL] [Abstract][Full Text] [Related]
7. Tumor markers in endometriosis.
Abrão MS; Podgaec S; Pinotti JA; de Oliveira RM
Int J Gynaecol Obstet; 1999 Jul; 66(1):19-22. PubMed ID: 10458545
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the clinical value of CA 19-9 versus CA 125 for the diagnosis of endometriosis.
Kurdoglu Z; Gursoy R; Kurdoglu M; Erdem M; Erdem O; Erdem A
Fertil Steril; 2009 Nov; 92(5):1761-3. PubMed ID: 19631319
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
11. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.
Reiter MJ; Costello JE; Schwope RB; Lisanti CJ; Osswald MB
J Comput Assist Tomogr; 2015; 39(6):825-34. PubMed ID: 26248153
[TBL] [Abstract][Full Text] [Related]
12. Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers.
Tsao KC; Wu TL; Chang PY; Hong JH; Wu JT
J Clin Lab Anal; 2006; 20(2):42-6. PubMed ID: 16538643
[TBL] [Abstract][Full Text] [Related]
13. High levels of CA125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review.
Ghaemmaghami F; Karimi Zarchi M; Hamedi B
Arch Gynecol Obstet; 2007 Nov; 276(5):559-61. PubMed ID: 17497163
[TBL] [Abstract][Full Text] [Related]
14. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis.
Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M
Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914
[TBL] [Abstract][Full Text] [Related]
15. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tumour markers in endometrial cancer.
Lo SS; Cheng DK; Ng TY; Wong LC; Ngan HY
Tumour Biol; 1997; 18(4):241-9. PubMed ID: 9218009
[TBL] [Abstract][Full Text] [Related]
17. Preoperative CA-125, CA 19-9 and nuclear magnetic resonance in endometrial carcinoma: correlation with surgical stage.
Schneider J; Centeno M; Sáez F; Genollá J; Ruibal A
Tumour Biol; 1999; 20(1):25-9. PubMed ID: 9858872
[TBL] [Abstract][Full Text] [Related]
18. Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation.
Masahashi T; Matsuzawa K; Ohsawa M; Narita O; Asai T; Ishihara M
Obstet Gynecol; 1988 Sep; 72(3 Pt 1):328-31. PubMed ID: 3165507
[TBL] [Abstract][Full Text] [Related]
19. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
20. Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Suzuki M; Usui N; Furugen Y; Mitsuhasi N
Int J Clin Oncol; 2001 Feb; 6(1):19-24. PubMed ID: 11706522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
